TherapeuticsMD (TXMD) Stock Forecast, Price Target & Predictions
TXMD Stock Forecast
TherapeuticsMD stock forecast is as follows: a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
TXMD Analyst Ratings
According to 1 Wall Street analysts, TherapeuticsMD's rating consensus is 'Buy'. The analyst rating breakdown for TXMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Mar 15, 2022 | Cantor Fitzgerald | Overweight | Overweight | Hold |
TherapeuticsMD's last stock rating was published by Cantor Fitzgerald on Mar 15, 2022. The company gave TXMD a "Overweight" rating, the same as its previous rate.
TherapeuticsMD Financial Forecast
TherapeuticsMD Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | $-53.00K | - | $416.00K | $1.15M | $20.92M | - | $19.33M | $18.68M | $25.41M | $23.00M | $19.87M | $22.58M | $19.34M | $10.70M | $12.25M | $15.90M | $23.72M | $6.08M | $3.95M | $5.09M | $3.47M | $3.76M | $3.77M | $4.12M | $4.42M |
| Avg Forecast | $2.30M | $2.30M | $2.20M | $2.20M | $600.00K | $500.00K | $500.00K | $1.70M | $26.80M | $23.20M | $17.95M | $29.39M | $25.87M | $22.11M | $19.77M | $21.14M | $15.47M | $10.38M | $11.38M | $12.82M | $8.13M | $5.12M | $5.96M | $4.19M | $5.09M | $4.56M | $3.01M | $3.43M | $3.30M | $6.95M |
| High Forecast | $2.30M | $2.30M | $2.20M | $2.20M | $600.00K | $500.00K | $500.00K | $1.70M | $26.80M | $23.20M | $17.95M | $29.39M | $25.87M | $22.11M | $19.77M | $21.14M | $15.47M | $10.38M | $11.38M | $12.82M | $8.13M | $5.12M | $5.96M | $5.03M | $6.11M | $5.47M | $3.61M | $4.11M | $3.96M | $8.33M |
| Low Forecast | $2.30M | $2.30M | $2.20M | $2.20M | $600.00K | $500.00K | $500.00K | $1.70M | $26.80M | $23.20M | $17.95M | $29.39M | $25.87M | $22.11M | $19.77M | $21.14M | $15.47M | $10.38M | $11.38M | $12.82M | $8.13M | $5.12M | $5.96M | $3.35M | $4.07M | $3.65M | $2.41M | $2.74M | $2.64M | $5.56M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 12 | 20 | 17 | 15 | 10 | 12 | 20 |
| Surprise % | - | - | - | - | - | -0.11% | - | 0.24% | 0.04% | 0.90% | - | 0.66% | 0.72% | 1.15% | 1.16% | 0.94% | 1.46% | 1.86% | 0.94% | 0.96% | 1.96% | 4.63% | 1.02% | 0.94% | 1.00% | 0.76% | 1.25% | 1.10% | 1.25% | 0.64% |
TherapeuticsMD's average Quarter revenue forecast for Dec 23 based on 1 analysts is $600.00K, with a low forecast of $600.00K, and a high forecast of $600.00K. TXMD's average Quarter revenue forecast represents a -1232.08% decrease compared to the company's last Quarter revenue of $-53.00K (Sep 23).
TherapeuticsMD EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 12 | 20 | 17 | 15 | 10 | 12 | 20 |
| EBITDA | - | - | - | - | - | $-1.28M | - | $-2.23M | $109.59M | $-25.86M | - | $-34.18M | $-34.38M | $-40.35M | $-34.01M | $-28.14M | $-33.45M | $-23.91M | $-43.94M | $-49.58M | $-42.76M | $-26.21M | $-51.09M | $-37.31M | $-37.20M | $-33.48M | $-32.62M | $-24.34M | $-21.37M | $-14.61M |
| Avg Forecast | $-1.70M | $-1.70M | $-1.63M | $-40.57M | $-443.42K | $-369.51K | $-369.51K | $-36.88M | $-59.50M | $-17.15M | $-13.27M | $-33.53M | $-54.09M | $-36.31M | $-34.01M | $-30.48M | $-11.43M | $-27.33M | $-38.77M | $-44.36M | $-42.76M | $-34.49M | $-33.06M | $-39.50M | $-37.20M | $-41.45M | $-24.47M | $-21.91M | $-16.03M | $-19.92M |
| High Forecast | $-1.70M | $-1.70M | $-1.63M | $-32.46M | $-443.42K | $-369.51K | $-369.51K | $-29.51M | $-47.60M | $-17.15M | $-13.27M | $-26.82M | $-43.27M | $-29.05M | $-27.21M | $-24.39M | $-11.43M | $-21.86M | $-31.02M | $-35.49M | $-34.21M | $-27.59M | $-26.45M | $-31.60M | $-29.76M | $-33.16M | $-19.57M | $-17.53M | $-12.82M | $-15.94M |
| Low Forecast | $-1.70M | $-1.70M | $-1.63M | $-48.69M | $-443.42K | $-369.51K | $-369.51K | $-44.26M | $-71.40M | $-17.15M | $-13.27M | $-40.24M | $-64.91M | $-43.58M | $-40.82M | $-36.58M | $-11.43M | $-32.79M | $-46.52M | $-53.23M | $-51.31M | $-41.38M | $-39.67M | $-47.40M | $-44.64M | $-49.74M | $-29.36M | $-26.29M | $-19.23M | $-23.91M |
| Surprise % | - | - | - | - | - | 3.47% | - | 0.06% | -1.84% | 1.51% | - | 1.02% | 0.64% | 1.11% | 1.00% | 0.92% | 2.93% | 0.88% | 1.13% | 1.12% | 1.00% | 0.76% | 1.55% | 0.94% | 1.00% | 0.81% | 1.33% | 1.11% | 1.33% | 0.73% |
1 analysts predict TXMD's average Quarter EBITDA for Mar 23 to be $-36.88M, with a high of $-29.51M and a low of $-44.26M. This is -133.66% lower than TherapeuticsMD's previous annual EBITDA (Dec 22) of $109.59M.
TherapeuticsMD Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 12 | 20 | 17 | 15 | 10 | 12 | 20 |
| Net Income | - | - | - | - | - | $-3.38M | - | $-3.60M | $-33.22M | $-28.96M | - | $-71.81M | $-50.54M | $-47.42M | $-42.65M | $-39.38M | $-42.09M | $-32.61M | $-51.98M | $-56.85M | $-49.44M | $-31.97M | $-55.24M | $-39.51M | $-39.39M | $-35.61M | $-33.22M | $-24.40M | $-21.43M | $-14.66M |
| Avg Forecast | $461.28K | $461.28K | $345.96K | $-56.79M | $-1.50M | $-1.73M | $-807.24K | $-51.62M | $-68.79M | $-35.06M | $-46.13M | $-46.93M | $-62.54M | $-42.68M | $-42.65M | $-42.66M | $-77.43M | $-37.27M | $-45.86M | $-50.86M | $-49.44M | $-42.06M | $-35.74M | $-41.83M | $-39.39M | $-44.08M | $-24.91M | $-21.96M | $-16.07M | $-20.00M |
| High Forecast | $461.28K | $461.28K | $345.96K | $-45.43M | $-1.50M | $-1.73M | $-807.24K | $-41.30M | $-55.03M | $-35.06M | $-46.13M | $-37.55M | $-50.03M | $-34.14M | $-34.12M | $-34.13M | $-77.43M | $-29.82M | $-36.69M | $-40.69M | $-39.55M | $-33.65M | $-28.59M | $-33.46M | $-31.51M | $-35.27M | $-19.93M | $-17.57M | $-12.86M | $-16.00M |
| Low Forecast | $461.28K | $461.28K | $345.96K | $-68.14M | $-1.50M | $-1.73M | $-807.24K | $-61.95M | $-82.55M | $-35.06M | $-46.13M | $-56.32M | $-75.04M | $-51.21M | $-51.18M | $-51.20M | $-77.43M | $-44.72M | $-55.03M | $-61.04M | $-59.32M | $-50.47M | $-42.89M | $-50.20M | $-47.27M | $-52.90M | $-29.90M | $-26.35M | $-19.28M | $-24.00M |
| Surprise % | - | - | - | - | - | 1.95% | - | 0.07% | 0.48% | 0.83% | - | 1.53% | 0.81% | 1.11% | 1.00% | 0.92% | 0.54% | 0.88% | 1.13% | 1.12% | 1.00% | 0.76% | 1.55% | 0.94% | 1.00% | 0.81% | 1.33% | 1.11% | 1.33% | 0.73% |
TherapeuticsMD's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. TXMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
TherapeuticsMD SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 12 | 20 | 17 | 15 | 10 | 12 | 20 |
| SG&A | - | - | - | - | - | $1.59M | - | $3.06M | $-59.24M | $36.76M | - | $39.30M | $47.91M | $58.44M | $52.04M | $42.41M | $49.21M | $39.01M | $48.60M | $57.19M | $52.98M | $45.27M | $41.50M | $34.97M | $35.51M | $30.43M | $29.53M | $20.82M | $14.24M | $12.11M |
| Avg Forecast | $7.57M | $7.57M | $7.24M | $7.24M | $1.97M | $1.65M | $1.65M | $5.60M | $88.21M | $76.36M | $59.09M | $96.73M | $85.15M | $72.79M | $65.06M | $69.59M | $50.91M | $34.15M | $37.45M | $42.21M | $26.75M | $16.85M | $19.62M | $13.80M | $16.75M | $15.01M | $9.90M | $11.28M | $10.85M | $22.86M |
| High Forecast | $7.57M | $7.57M | $7.24M | $7.24M | $1.97M | $1.65M | $1.65M | $5.60M | $88.21M | $76.36M | $59.09M | $96.73M | $85.15M | $72.79M | $65.06M | $69.59M | $50.91M | $34.15M | $37.45M | $42.21M | $26.75M | $16.85M | $19.62M | $16.56M | $20.10M | $18.01M | $11.88M | $13.54M | $13.02M | $27.43M |
| Low Forecast | $7.57M | $7.57M | $7.24M | $7.24M | $1.97M | $1.65M | $1.65M | $5.60M | $88.21M | $76.36M | $59.09M | $96.73M | $85.15M | $72.79M | $65.06M | $69.59M | $50.91M | $34.15M | $37.45M | $42.21M | $26.75M | $16.85M | $19.62M | $11.04M | $13.40M | $12.00M | $7.92M | $9.02M | $8.68M | $18.29M |
| Surprise % | - | - | - | - | - | 0.97% | - | 0.55% | -0.67% | 0.48% | - | 0.41% | 0.56% | 0.80% | 0.80% | 0.61% | 0.97% | 1.14% | 1.30% | 1.36% | 1.98% | 2.69% | 2.12% | 2.53% | 2.12% | 2.03% | 2.98% | 1.85% | 1.31% | 0.53% |
TherapeuticsMD's average Quarter SG&A projection for Dec 23 is $1.97M, based on 1 Wall Street analysts, with a range of $1.97M to $1.97M. The forecast indicates a 24.20% rise compared to TXMD last annual SG&A of $1.59M (Sep 23).
TherapeuticsMD EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 | Dec 17 | Sep 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | - | - | 6 | 10 | 10 | 10 | 10 | 5 | 5 | 5 | 12 | 20 | 17 | 15 | 10 | 12 | 20 |
| EPS | - | - | - | - | - | $-0.32 | - | $-0.37 | $-3.68 | $-3.13 | - | $-8.34 | $-0.12 | $-0.11 | $-0.11 | $-0.11 | $-0.15 | $-0.12 | $-0.19 | $-0.21 | $-0.19 | $-0.13 | $-0.23 | $-0.16 | $-0.17 | $-0.16 | $-0.15 | $-0.11 | $-0.10 | $-0.07 |
| Avg Forecast | $0.04 | $0.04 | $0.03 | $0.03 | $-0.13 | $-0.15 | $-0.07 | $0.06 | $-0.57 | $-3.04 | $-4.00 | $-3.83 | $-5.00 | $-5.50 | $-6.13 | $-5.30 | $-6.71 | $-8.31 | $-9.51 | $-9.23 | $-9.42 | $-8.64 | $-8.33 | $-0.18 | $-0.17 | $-0.26 | $-0.09 | $-0.09 | $-0.06 | $-0.15 |
| High Forecast | $0.04 | $0.04 | $0.03 | $0.03 | $-0.13 | $-0.15 | $-0.07 | $0.06 | $-0.57 | $-3.04 | $-4.00 | $-3.83 | $-5.00 | $-5.50 | $-6.13 | $-5.30 | $-6.71 | $-8.31 | $-9.51 | $-9.23 | $-9.42 | $-8.64 | $-8.33 | $-0.14 | $-0.14 | $-0.21 | $-0.07 | $-0.07 | $-0.05 | $-0.12 |
| Low Forecast | $0.04 | $0.04 | $0.03 | $0.03 | $-0.13 | $-0.15 | $-0.07 | $0.06 | $-0.57 | $-3.04 | $-4.00 | $-3.83 | $-5.00 | $-5.50 | $-6.13 | $-5.30 | $-6.71 | $-8.31 | $-9.51 | $-9.23 | $-9.42 | $-8.64 | $-8.33 | $-0.22 | $-0.20 | $-0.31 | $-0.11 | $-0.11 | $-0.07 | $-0.18 |
| Surprise % | - | - | - | - | - | 2.13% | - | -6.17% | 6.46% | 1.03% | - | 2.18% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.01% | 0.02% | 0.02% | 0.02% | 0.02% | 0.03% | 0.89% | 1.00% | 0.62% | 1.67% | 1.22% | 1.67% | 0.47% |
According to undefined Wall Street analysts, TherapeuticsMD's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to TXMD previous annual EPS of $NaN (undefined).
TherapeuticsMD Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TXMD | TherapeuticsMD | $1.58 | $5.00 | 216.46% | Buy |
| IRWD | Ironwood Pharmaceuticals | $4.50 | $11.67 | 159.33% | Buy |
| AQST | Aquestive Therapeutics | $4.93 | $9.50 | 92.70% | Buy |
| ORGO | Organogenesis | $3.25 | $5.00 | 53.85% | Buy |
| LFCR | Lifecore Biomedical | $4.61 | $6.50 | 41.00% | Buy |
| ANIP | ANI Pharmaceuticals | $59.66 | $79.00 | 32.42% | Buy |
| ALKS | Alkermes | $28.09 | $35.71 | 27.13% | Hold |
| CYTH | Cyclo Therapeutics | $0.79 | $0.95 | 20.25% | Buy |
| AGRX | Agile Therapeutics | $1.51 | $1.00 | -33.77% | Buy |
| GHSI | Guardion Health Sciences | $3.25 | $0.01 | -99.69% | Buy |
TXMD Forecast FAQ
Is TherapeuticsMD a good buy?
Yes, according to 1 Wall Street analysts, TherapeuticsMD (TXMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of TXMD's total ratings.
What are TherapeuticsMD's analysts' financial forecasts?
TXMD's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $9M (high $9M, low $9M), average EBITDA is $-45.597M (high $-37.482M, low $-53.711M), average net income is $-55.518M (high $-44.161M, low $-66.876M), average SG&A $29.62M (high $29.62M, low $29.62M), and average EPS is $0.14 (high $0.14, low $0.14).
Did the TXMD's actual financial results beat the analysts' financial forecasts?
Based on TherapeuticsMD's last annual report (Dec 2023), the company's revenue was $1.3M, which missed the average analysts forecast of $3.3M by -60.55%. Apple's EBITDA was $-6.734M, missing the average prediction of $-38.065M by -82.31%. The company's net income was $-7.699M, missing the average estimation of $-55.661M by -86.17%. Apple's SG&A was $8.9M, missing the average forecast of $10.86M by -18.03%. Lastly, the company's EPS was $-0.74, beating the average prediction of $-0.29 by 155.17%. In terms of the last quarterly report (Sep 2023), TherapeuticsMD's revenue was $-53K, missing the average analysts' forecast of $500K by -110.60%. The company's EBITDA was $-1.284M, beating the average prediction of $-370K by 247.48%. TherapeuticsMD's net income was $-3.378M, beating the average estimation of $-1.73M by 95.28%. The company's SG&A was $1.59M, missing the average forecast of $1.65M by -3.38%. Lastly, the company's EPS was $-0.32, beating the average prediction of $-0.15 by 113.33%